Can Aspirin Use Be Interrupted After Angioplasty?

Aspirin discontinuation 1 to 3 months after angioplasty with continued P2Y12 inhibitor therapy reduces the bleeding risk without an increase in thrombotic events. This is also the case for patients admitted with acute coronary syndrome.

¿Se puede suspender la aspirina luego de una angioplastia?

Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has been shown to reduce the risk of major events compared with aspirin alone after angioplasty or acute coronary syndrome. Its price? An increased risk of bleeding.

The safety of discontinuing aspirin in favor of P2Y12 inhibitor monotherapy (as opposed to the standard of care) remains controversial.

To gather supporting evidence, this meta-analysis of 5 randomized studies with follow-up periods from 12 to 15 months was conducted.

In all studies, aspirin was interrupted 1 to 3 months post-angioplasty with continued P2Y12 inhibitor monotherapy compared with traditional dual antiplatelet therapy.


Read also: Virtual ACC 2020 | VOYAGER PAD: Rivaroxaban Superior to Aspirin in Preventing Events.


The study population included 32,145 patients who underwent an angioplasty—over half of them, 56.1%, had an acute coronary syndrome.

In the experimental arm, 16.5% of patients continued taking a clopidogrel monotherapy, while 83.5% received prasugrel or ticagrelor.

Discontinuation of aspirin therapy 1 to 3 months after angioplasty reduced the risk of major bleeding by 40% compared with standard dual antiplatelet therapy (1.97% vs. 3.13%; hazard ratio [HR]: 0.60; 95% confidence interval [CI]: 0.45-0.79).


Read also: Alternatives for Patients Allergic to Aspirin.


This discontinuation did not increase the risk of thrombotic events (2.73% vs. 3.11%; HR: 0.88; 95% CI: 0.77-1.02).

Findings were consistent among patients who underwent angioplasty in a setting of acute coronary syndrome, reducing the risk of bleeding even more than in the general population (50%, comparatively). In this higher-risk population, there was no increase in the risk of thrombotic events.

Original Title: The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention. A Systematic Review and Meta-Analysis.

Reference: Michelle L. O’Donoghue et al. Circulation. 2020;142:538–545.  DOI: 10.1161/CIRCULATIONAHA.120.046251.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....